Jason Cohen, Editor

About the Author Jason Cohen, Editor


Cantor Boosts Price Target for Ignyta Inc (RXDX) on Back of Positive Clinical Data

ROS1-Positive interim data raises Mara Goldstein’s conviction.

Read more

H.C. Wainwright Pounds the Table on Synergy Pharmaceuticals Inc (SGYP)

H.C. Wainwright analyst Ram Selvaraju was out pounding the table on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) …

Read more

Antares Pharma Inc (ATRS) and AcelRx Pharmaceuticals Inc (ACRX) Fail to Meet FDA Threshold; Analysts Weigh In

The complete response letter: Antares and AcelRx have just gotten the kind of mail no one wants to receive.

Read more

Mara Goldstein Sees 80% Upside for Ardelyx Inc (ARDX) Following Clinical Trial Victory

Ardelyx’s drug tenapanor gets closer to FDA approval; Cantor’s Mara Goldstein weighs in.

Read more

Mara Goldstein Bullish on Ardelyx Inc (ARDX) as IBS-C Trial Delivers Positive Results

Tenapanor is a viable drug in the treatment of IBS-C, says Cantor’s Mara Goldstein.

Read more

Aerie Pharmaceuticals Inc’s (AERI) Glaucoma Drug Is Poised for a Favorable AdCom: Cantor

No surprises within Rhopressa briefing documents – Good news for Aerie investors.

Read more

Jason Kolbert Boosts Price Target for MannKind Corporation (MNKD) to $7; Here’s Why

Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.

Read more

BTIG Remains Buyer of Vericel Corp (VCEL) on Core Business Value

BTIG feels confident in Vericel core business as ixmyelocel-T’s future became uncertain.

Read more

ACADIA Pharmaceuticals Inc. (ACAD) Hits New 52-Week High Following Breakthrough Therapy Designation; J.P. Morgan Weighs In

ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.

Read more

Analysts Say Buy Sarepta Therapeutics Inc (SRPT) Shares, Ignore Patient Deaths

Sarepta shares dropped 4% after patient deaths revealed in the FDA FAERS database.

Read more